| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1Department of Respiratory Medicine, 2Division of Biomedical Imaging Research, Biomedical Research Center, Juntendo University School of Medicine; and 3Division of Respiratory Medicine, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan
Submitted 6 May 2005 ; accepted in final form 7 October 2005
Heterozygous mutations in the type II receptor for bone morphogenetic protein (BMPR-II) and dysfunction of BMPR-II have been implicated in patients with primary pulmonary hypertension (PH). To clarify the possible involvement of BMP and BMPR-II in the development of hypoxic PH, the expression of BMP-2, BMPR-II, and their downstream signals were investigated in rat lung under normal and hypoxic conditions by RT-PCR, immunoblot, and immunohistochemical methods. In rats under normal conditions, BMP-2 is localized in the endothelium of the pulmonary artery, whereas BMPR-II is abundantly expressed in the endothelium, smooth muscle cells, and adventitial fibroblasts. After 0.5 and 3 days of exposure to hypoxia, upregulation of BMP-2 was observed in the intrapulmonary arteries. The change was accompanied by activation of its downstream signaling, p38 MAPK, and Erk1/2 MAPK, and the apoptotic process, measured by caspase-3 activity and TdT-mediated dUTP nick end labeling-positive cells. In contrast, a significant decrease in the expression of BMPR-II and inactivation of p38 MAPK and caspase-3 were observed in the pulmonary vasculature after 7–21 days of hypoxia exposure. Because BMP-2 is known to inhibit proliferation of vascular smooth muscle cells and promote cellular apoptosis, disruption of BMP signaling pathway through downregulation of BMPR-II in chronic hypoxia may result in pulmonary vascular remodeling due to the failure of critical antiproliferative/differentiation programs in the pulmonary vasculature. These results suggest abrogation of BMP signaling may be a common molecular pathogenesis in the development of PH with various pathophysiological events, including primary and hypoxic PH.
apoptosis; p38 mitogen-activated protein kinase; Erk1/2 mitogen-activated protein kinase
This article has been cited by other articles:
|
|
 |
|
  N. W. Morrell, S. Adnot, S. L. Archer, J. Dupuis, P. Lloyd Jones, M. R. MacLean, I. F. McMurtry, K. R. Stenmark, P. A. Thistlethwaite, N. Weissmann, et al. Cellular and Molecular Basis of Pulmonary Arterial Hypertension J. Am. Coll. Cardiol., June 30, 2009; 54(1_Suppl_S): S20 - S31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brock, M. Trenkmann, R. E. Gay, B. A. Michel, S. Gay, M. Fischler, S. Ulrich, R. Speich, and L. C. Huber Interleukin-6 Modulates the Expression of the Bone Morphogenic Protein Receptor Type II Through a Novel STAT3-microRNA Cluster 17/92 Pathway Circ. Res., May 22, 2009; 104(10): 1184 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Long, A. Crosby, X. Yang, M. Southwood, P. D. Upton, D.-K. Kim, and N. W. Morrell Altered Bone Morphogenetic Protein and Transforming Growth Factor-{beta} Signaling in Rat Models of Pulmonary Hypertension: Potential for Activin Receptor-Like Kinase-5 Inhibition in Prevention and Progression of Disease Circulation, February 3, 2009; 119(4): 566 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Wu, N. B. Dave, G. Yu, P. J. Strollo, E. Kovkarova-Naumovski, S. W. Ryter, S. R. Reeves, E. Dayyat, Y. Wang, A. M. K. Choi, et al. Network analysis of temporal effects of intermittent and sustained hypoxia on rat lungs Physiol Genomics, December 12, 2008; 36(1): 24 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Costello, K. Howell, E. Cahill, J. McBryan, M. Konigshoff, O. Eickelberg, S. Gaine, F. Martin, and P. McLoughlin Lung-selective gene responses to alveolar hypoxia: potential role for the bone morphogenetic antagonist gremlin in pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, August 1, 2008; 295(2): L272 - L284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. El-Bizri, L. Wang, S. L. Merklinger, C. Guignabert, T. Desai, T. Urashima, A. Y. Sheikh, R. H. Knutsen, R. P. Mecham, Y. Mishina, et al. Smooth Muscle Protein 22{alpha}-Mediated Patchy Deletion of Bmpr1a Impairs Cardiac Contractility but Protects Against Pulmonary Vascular Remodeling Circ. Res., February 15, 2008; 102(3): 380 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Frank, J. Lowery, L. Anderson, M. Brink, J. Reese, and M. de Caestecker Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature Am J Physiol Lung Cell Mol Physiol, January 1, 2008; 294(1): L98 - L109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Sehgal, S. Mukhopadhyay, F. Xu, K. Patel, and M. Shah Dysfunction of Golgi tethers, SNAREs, and SNAPs in monocrotaline-induced pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1526 - L1542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Reynolds, W. Xia, M. D. Holmes, S. J. Hodge, S. Danilov, D. T. Curiel, N. W. Morrell, and P. N. Reynolds Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1182 - L1192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. W. Morrell Pulmonary Hypertension Due to BMPR2 Mutation: A New Paradigm for Tissue Remodeling? Proceedings of the ATS, November 1, 2006; 3(8): 680 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ihida-Stansbury, D. M. McKean, K. B. Lane, J. E. Loyd, L. A. Wheeler, N. W. Morrell, and P. L. Jones Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L694 - L702. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
